Our data showed that OTX015 treatment did not cause an increase in the expression of these HIV receptors/co-receptors (Fig. 6), suggesting that OTX015 may not pose the risk of increasing the susceptibility of CD4+ T cells to HIV-1 infection during the reactivation of HIV-1 latency. The gene discussed is CD4; the disease is HIV-1 infection.